Gilead Sciences Inc. announced that it would begin selling generic versions of the company’s two leading treatments for hepatitis C at substantially reduced prices. The generic versions of Epclusa and…
Yesterday, four national hospital groups and three hospital systems filed a lawsuit against HHS over the continued delay of the implementation date of the 340B Ceiling Price and Manufacturer Civil…
Yesterday, hospital groups filed a second lawsuit challenging a nearly 30% reduction to Medicare Part B reimbursement for 340B drugs that went into effect January 1, 2018. The hospital originally…